Circulating intercellular adhesion molecule-1 (ICAM-1) and tissue inhibitor of metalloproteinases-1 (TIMP-1) have been widely proposed as potential diagnostic biomarkers for pancreatic ductal adenocarcinoma (PDAC). We report on serum protein levels prior to clinical presentation of pancreatic cancer. Serum ICAM-1 and TIMP-1 were measured by ELISA in two case-control sets 1) samples from patients diagnosed with pancreatic cancer (n=40), chronic pancreatitis (n=20), benign jaundice due to gall stones (n=20) and healthy subjects (n=20); 2) a preclinical set from the UK Collaborative Trial of Ovarian Cancer Screening biobank of samples collected from 27 post-menopausal women 0-12 months prior to diagnosis of pancreatic cancer and controls matched for date of donation and centre. Levels of ICAM-1 and TIMP-1 were significantly elevated in set 1 in PDAC patients with jaundice compared to PDAC patients without jaundice and both proteins were elevated in patients with jaundice due to gall stones. Neither protein was elevated in samples taken 0-12 months prior to PDAC diagnosis compared to non-cancer control samples. In conclusion, evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer. Failure to account for obstructive jaundice may have contributed to the previous promise of these candidate biomarkers.
Key words: ICAM-1, TIMP-1, pancreatic cancer, serum biomarker, UKCTOCS To the editor Pancreatic ductal adenocarcinoma (PDAC) is usually diagnosed when the disease is advanced. This limits therapeutic options and biomarkers for earlier diagnosis are sought (1) . Using blood taken at diagnosis of PDAC to identify biomarkers poses intrinsic challenges. The levels of blood proteins at diagnosis may accurately represent advanced disease, but might not necessarily reflect levels prior to diagnosis. In addition, the sensitivity of some markers for the detection of PDAC over healthy controls was recently shown to be considerably higher for PDAC patients in the presence of obstructive jaundice compared to PDAC patients in the absence of obstructive jaundice (2) . Two serum proteins, identified in several studies as potential diagnostic biomarkers due to their upregulation in PDAC, are ICAM-1 (3-6) and TIMP-1 (3) (4) (5) (7) (8) (9) (10) . In order to determine whether ICAM-1 and TIMP-1 levels are affected by biliary obstruction we compared samples (Liverpool cohort) taken at diagnosis from patients with PDAC (in the presence or absence of jaundice), chronic pancreatitis, benign biliary obstruction or from healthy controls. In patients with PDAC, both ICAM-1 and TIMP-1 levels were significantly higher than in healthy controls ( Figure 1a and b), as previously reported (3) (4) (5) (6) (7) (8) (9) (10) . PDAC patients with biliary obstruction (bilirubin levels >20 µmol/L) had significantly higher levels of both ICAM-1 (p<0.001) and TIMP-1 (p=0.024) than PDAC patients without biliary obstruction (bilirubin levels <20 µmol/L). ICAM-1 and TIMP-1 levels were also elevated in patients with biliary obstruction due to gall stones (p<0.0001 for ICAM-1 and p=0.0001 TIMP-1). Finally these proteins only distinguished PDAC from chronic pancreatitis when the PDAC patients had biliary obstruction (p=0.004 for ICAM-1 and p=0.014 for TIMP-1, Figure 1a and b).
Secondly, to determine if these proteins are raised prior to clinical presentation of pancreatic cancer, we analysed pre-diagnostic samples collected as part of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) (11) , from individuals who went on to develop pancreatic cancer during the study, and compared them with their time matched cancer-free controls. No significant differences were observed between serum ICAM-1 or TIMP-1 from UKCTOCS cases (n=27) and matched controls (n=27) from the time period 0-12 months prior to PDAC diagnosis (Figure 1c and d) . Of note, although all of the individuals in the UKCTOCS cohort were female, the Liverpool cohort contained both males (59/100) and females (41/100). Neither ICAM-1 nor TIMP-1 were associated with gender or age in any group.
Our study shows that although the levels of both ICAM-1 and TIMP-1 were significantly raised at the time of diagnosis in cancer patients compared to healthy controls, the absolute increases observed in patients in the absence of biliary obstruction were relatively small compared to those seen in the presence of obstruction. Moreover, neither marker was effective in distinguishing patients with chronic pancreatitis from PDAC patients in the absence of biliary obstruction. We conclude that the initial promise of these two candidates as markers of pancreatic cancer was artificially inflated due to failure to account for biliary obstruction in cancer patients. Secondly we show that the levels of ICAM-1 and TIMP-1 are not significantly elevated in the months leading to a diagnosis of pancreatic cancer, and provide little support for the notion that either of these markers will be effective for early detection of pancreatic cancer. 5-69.6 ). Duplicate measurements gave an average CV of 6.4% (rho=0.966) for ICAM-1 and 9.9% (rho=0.991) for TIMP-1. Data were log transformed in order to remove skewness prior to analysis using JMP software, version 9.0.2. Groups were compared using ANOVA and t-tests; p values are shown on graphs for Liverpool cohort (* <0.05; ** <0.01; ***<0.001, ****<0.0001).
